FindTrial
Sign In

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Nemolizumab in Patients with Acquired Reactive Perforating Collagenosis

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Nemolizumab in Patients with Acquired Reactive Perforating Collagenosis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2021230034
Enrollment
21
Registered
2023-11-09
Start date
2023-12-04
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Reactive Perforating Collagenosis

Interventions

subcutaneous administration

Sponsors

Tomoyuki Nishiura
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients aged 18 years or older who have been diagnosed with acquired reactive perforating collagen fibrosis according to the diagnostic criteria of the Clinical Practice Guide for Perforated Dermatoses (2020)

Exclusion criteria

Exclusion criteria: Patients with immune deficiency Patients with body weight less than 30.0kg Patients with Hepatitis B virus or hepatitis C virus infection Patients with Evidence of tuberculosis (TB) infection Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Peak pruritus-Numeric rate scale (PP-NRS)—

Contacts

Public ContactClinical Trials Infomation -

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026